Knight Therapeutics Inc. (TSE:GUD) Given Consensus Rating of “Buy” by Analysts

Knight Therapeutics Inc. (TSE:GUD – Get Rating) has been given a consensus recommendation of “Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is C$7.00.

GUD has been the subject of several recent analyst reports. National Bank Financial reduced their price target on Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating for the company in a report on Friday, March 25th. Canaccord Genuity Group reduced their price target on Knight Therapeutics from C$8.00 to C$7.00 in a report on Friday, March 25th. Raymond James set a C$7.50 price target on Knight Therapeutics and gave the company an “outperform” rating in a report on Friday, April 1st. Bloom Burton reissued a “buy” rating and issued a C$6.70 price target on shares of Knight Therapeutics in a report on Monday, March 28th. Finally, Stifel Nicolaus cut Knight Therapeutics to a “hold” rating and set a C$5.30 price target for the company. in a report on Thursday, March 24th.

Shares of GUD stock traded up C$0.05 during midday trading on Wednesday, hitting C$5.30. The company had a trading volume of 16,600 shares, compared to its average volume of 217,070. The company’s 50 day simple moving average is C$5.32 and its 200 day simple moving average is C$5.35. Knight Therapeutics has a 52-week low of C$5.01 and a 52-week high of C$5.74. The stock has a market cap of C$611.03 million and a price-to-earnings ratio of -96.55. The company has a debt-to-equity ratio of 5.64, a current ratio of 2.73 and a quick ratio of 2.05.

Knight Therapeutics (TSE:GUD – Get Rating) last announced its earnings results on Thursday, May 12th. The company reported C($0.02) earnings per share for the quarter, beating the consensus estimate of C($0.04) by C$0.02. The company had revenue of C$63.81 million during the quarter, compared to analysts’ expectations of C$52.80 million. Analysts anticipate that Knight Therapeutics will post -0.02 EPS for the current year.

In related news, insider Long Zone Holdings Inc. purchased 20,000 shares of the business’s stock in a transaction dated Wednesday, May 18th. The stock was bought at an average cost of C$5.17 per share, with a total value of C$103,400.00. Following the completion of the acquisition, the insider now directly owns 21,705,933 shares in the company, valued at approximately C$112,219,673.61. Also, Director Samira Sakhia purchased 19,305 shares of the business’s stock in a transaction dated Wednesday, May 18th. The stock was bought at an average cost of C$5.18 per share, with a total value of C$99,999.90. Following the completion of the acquisition, the director now owns 136,734 shares of the company’s stock, valued at C$708,282.12. Over the last ninety days, insiders have purchased 41,205 shares of company stock valued at $213,470.

About Knight Therapeutics (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

Featured Stories